DiaSorin S.p.A. (IT:DIA) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
DiaSorin S.p.A. reported a strong performance for the first nine months of 2024, with revenues reaching €876 million, a 4% increase at constant exchange rates, and an impressive 7% growth excluding COVID-related sales. The company’s adjusted EBITDA also improved, marking a 6% rise, reflecting a robust profitability trend across all business lines, notably in immunodiagnostics and molecular diagnostics. As a result, DiaSorin has raised its revenue guidance for the 2024 financial year, emphasizing continued growth in non-COVID sectors.
For further insights into IT:DIA stock, check out TipRanks’ Stock Analysis page.
